Natera Q3 2025: Revenue Up 34.7%, Guidance Raised

Published: November 6, 2025

Natera, Inc.

Direct News

Natera (NTRA) reports 34.7% revenue growth in Q3 2025 and says it has raised 2025 guidance.
Product revenues in Q3 2025: $590.2M (99.7% of total revenues of $592.2M).
Nine-month 2025 product revenues: $1,634.7M, up 35% year-over-year.
Key growth drivers cited: Signatera (tumor-informed ctDNA), Panorama (NIPT) and Horizon (carrier screening).
Company reports a single reporting segment: molecular testing services.
Material risks highlighted: FDA LDT rule changes, reimbursement uncertainty, supplier concentration and lab capacity constraints.

Historical context

Q3 2025 continues a multi-quarter growth trend for Natera. Earlier in 2025, the company posted implied product revenue progress across quarters (Q1 around $500M implied; Q2 product revenues $544.4M, +32% YoY), leading to the Q3 product total of $590.2M. The nine-month product revenue tally of $1,634.7M represents roughly 35% year-over-year growth, showing sustained demand across the company's core franchises. Natera reports one operating segment—molecular testing services—and discloses heavy reliance on Signatera, Panorama and Horizon for the foreseeable future. While the company's proprietary mmPCR and tumor-informed ctDNA approaches underpin clinical differentiation, filings do not identify a structural economic moat; instead, growth has been portrayed as dependent on execution, payer coverage expansion and continued clinical validation.

Q3 results and guidance — what happened

Natera reported robust top-line momentum in Q3 2025, highlighting a 34.7% revenue increase and announcing an upward revision to full-year 2025 guidance. The quarter was driven overwhelmingly by product revenue: $590.2 million of product sales accounted for 99.7% of the quarter's $592.2 million in total revenue. On a year-to-date basis, product revenues through nine months reached $1,634.7 million, up about 35% year-over-year. Management attributed the gain to continued adoption of its core molecular testing products, notably Signatera for tumor-informed ctDNA monitoring, along with growth in Panorama and Horizon in women's health. The company continues to report as a single segment—molecular testing services—so investors should view the results as consolidated demand for its cfDNA-based product suite rather than a segmented diversification story.

Investor implications and near-term catalysts

The raise to 2025 guidance signals confidence in the commercial traction of Signatera and the broader product mix. For investors, key near-term considerations include payer coverage trends (Medicare exposure and private payer reimbursement), clinical adoption of MRD and recurrence monitoring, and the company's ability to scale lab capacity while managing supply-chain concentration. Natera's clinical positioning—mmPCR SNP-based assays and tumor-informed approaches—is a clear commercial differentiator, but filings characterize that advantage more as execution-based than a structural moat. That nuance matters: strong execution can sustain growth in the near term, but the company remains exposed to reimbursement pressures and regulatory shifts that could change the adoption trajectory.

Risks highlighted by management

Natera's filings emphasize several risks that could influence the stock's performance despite the quarter's strength. Regulatory risk is front-and-center after the FDA's May 2024 rule changes on laboratory-developed tests, which introduce uncertainty around compliance timelines and costs. Reimbursement is another key variable — the company depends on third-party payers for the majority of its receivables and needs continued coverage expansion for Signatera and other tests. Operational risks include reliance on single-source suppliers for lab instruments and materials and the need to scale CLIA lab capacity to support higher volume. Investors should monitor payer decisions, any additional regulatory guidance affecting LDTs, and quarterly throughput metrics that indicate whether lab capacity and supply chains are keeping pace with demand.

Investor FAQ

The most effective approach is to maintain a factual perspective. Keep a close watch on further developments at Natera, Inc. as they unfold. Use primary source data to validate your investment thesis rather than relying on delayed secondary reports.

You can set up an automated tracker on Portrak. Our system monitors official SEC filings in real-time, delivering the most critical insights to your phone or inbox seconds after publication—frequently before the information reaches major financial news platforms.

We believe quality intelligence should be accessible. Our business model is supported by professional investors with large, complex portfolios who utilize Portrak Pro. These users pay to automate the monitoring of extensive watchlists, saving hundreds of hours in research time, which allows us to keep the standard service free for individual investors tracking their core positions.

Setting up your automated intelligence pipeline is a simple 3-step process:

Create Your Free Account

Select Your Focus

Use the search bar to find companies like Natera, Inc.. Choose between monitoring specific events or receiving general market-moving intelligence. Our AI automatically determines what’s critical based on real-time market data and the company’s current profile.

Receive Real-Time Intelligence

Once activated, all official filings are analyzed instantly. Insights are delivered directly to your email or as a push notification if you use the Portrak mobile app.

Also available as a mobile app for iOS & Android—search for "Portrak"